Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk

David R Janero Northeastern University, Center for Drug Discovery, 360 Huntington Avenue, 116 Mugar Hall, Boston, MA 02115-5000, USA+1 617 373 2208; +1 617 373 7493; [email protected]

Loren Lindsley Northeastern University, Center for Drug Discovery, 360 Huntington Avenue, 116 Mugar Hall, Boston, MA 02115-5000, USA+1 617 373 2208; +1 617 373 7493; [email protected];Novartis Institutes for BioMedical Research, Cardiovascular and Metabolism Disease Area, Cambridge, MA 02139, USA

Venkata Kiran Vemuri Northeastern University, Center for Drug Discovery, 360 Huntington Avenue, 116 Mugar Hall, Boston, MA 02115-5000, USA+1 617 373 2208; +1 617 373 7493; [email protected]

Alexandros Makriyannis Northeastern University, Center for Drug Discovery, 360 Huntington Avenue, 116 Mugar Hall, Boston, MA 02115-5000, USA+1 617 373 2208; +1 617 373 7493; [email protected]

Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date